Chief Scientist okays 17 projects

The Office of the Chief Scientist has approved 17 new research and development projects to be funded by its R&D Fund, the Ministry of Industry, Trade and Labor said Sunday.

By AVI KRAWITZ
February 12, 2007 07:38

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

The Office of the Chief Scientist has approved 17 new research and development projects to be funded by its R&D Fund, the Ministry of Industry, Trade and Labor said Sunday. The Chief Scientists office will cover NIS 16.2 million of the combined NIS 36.1m. R&D budget for the projects, the ministry said. Four of the projects are in the medical device field, two in chemical research, four in software, four in traditional industry and the remaining three in various other areas. Chief Scientist Eli Ofer said the ministry intends to increase its investment in traditional industry R&D from NIS 107m. last year to NIS 120m. in 2007 and to reach NIS 500m. by 2010.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS